Characterizing the performance of an antibiotic resistance prediction tool, gnomonicus, using a diverse test set of 2,663 Mycobacterium tuberculosis samples

Westhead J., Baker CS., Brouard M., Colpus M., Constantinides B., Hall A., Knaggs J., Alves ML., Spies R., Thai H., Surrall S., Govender K., Peto TEA., Crook DW., Omar SV., Turner R., Fowler PW.

Tuberculosis remains a global health problem. Making it easier and quicker to identify which antibiotics an infection is likely to be susceptible to will be a key part of the solution. Whilst whole-genome sequencing offers many advantages, the processing of the genetic reads to produce the relevant public health and clinical information is, surprisingly, often the responsibility of the end user, which inhibits uptake. Here, we characterize how well a freely available tool we have developed, gnomonicus, predicts the antibiotic resistance profile of a sample (given its variant call file) using our implementation of the second edition of the World Health Organization (WHO) catalogue of resistance-associated variants (WHOv2). To facilitate this, we have constructed a diverse test set of 2,663 publicly available Mycobacterium tuberculosis samples, which have both genetic and drug susceptibility testing (DST) data. We have chosen to apply the catalogue such that our tool will return a result of (i) Fail if there are insufficient reads at a genetic locus associated with resistance, (ii) Unknown if a genetic variant in a resistance gene not listed in the catalogue is encountered and (iii) Resistant if three or more short-reads support the presence of a resistance-associated variant. The last step increases the sensitivity for all 15 antibiotics but only reaches significance in a few in our test set. Comparing our results with those of TB-Profiler, an existing tool, highlights the different design choices and demonstrates that the performance of both tools on our diverse test set is comparable. By only considering high-confidence DST results, we show that gnomonicus, in combination with our translation of WHOv2, achieves sensitivities and specificities in excess of 95% for both isoniazid and rifampicin.

DOI

10.1099/mgen.0.001592

Type

Journal article

Publisher

Microbiology Society

Publication Date

2025-12-15T00:00:00+00:00

Volume

11

Permalink More information Close